Vlado Perkovic

Also affiliated with UNSW Sydney, The George Institute for Global Health, George Institute for Global Health

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 1%percentile

9.9Author DataRank

Indexed papers

2in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Why this DataRank?

An author's DataRank is the sum of the DataRanks of all 2 indexed papers attributed to them. A prolific author with many moderate-impact papers can outrank one with a single high-impact paper.

Author scores recompute whenever paper DataRanks are refreshed, so this number lags the underlying paper scores by at most one batch run.

Read the full methodology →

The highest-impact dataset this researcher has shared, ranked by DataRank — the single contribution doing the most to lift their data-sharing standing.

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

New England Journal of Medicine(2017)10.1056/nejmoa1611925

Top 1%

9.9DataRank

Top 1%7805 citations

Vlado Perkovic, Kenneth W. Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu +5 more

Papers

Driven by 32 papers — median percentile 99. Top paper: “Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes”.

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes

New England Journal of Medicine(2017)10.1056/nejmoa1611925

Top 1%

9.9DataRank

Top 1%7805 citations

Vlado Perkovic, Kenneth W. Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu +5 more

The rationale, design and baseline data of FLOW, a kidney outcomes trial with once-weekly semaglutide in people with type 2 diabetes and chronic kidney disease

Nephrology Dialysis Transplantation(2023)10.1093/ndt/gfad009

N/A

5.2DataRank · unranked

239 citations

Florian M.M. Baeres, George L. Bakris, Heidrun Bosch‐Traberg, Mette Gislum, Stephen Gough +9 more

Effect of SGLT2 Inhibitors on Stroke and Atrial Fibrillation in Diabetic Kidney Disease

Stroke(2021)10.1161/strokeaha.120.031623

N/A

3.6DataRank · unranked

120 citations

Meg Jardine, Qiang Li, Brendon L. Neuen, Christopher P. Cannon, Dick de Zeeuw +95 more

Kidney, Cardiovascular, and Safety Outcomes of Canagliflozin according to Baseline Albuminuria

Clinical Journal of the American Society of Nephrology(2021)10.2215/cjn.15260920

N/A

3.4DataRank · unranked

54 citations

Zien Zhou, Hiddo J.L. Heerspink, Carinna Hockham, Qiang Li, Rajiv Agarwal +18 more

Effects of Linagliptin on Cardiovascular and Kidney Outcomes in People With Normal and Reduced Kidney Function: Secondary Analysis of the CARMELINA Randomized Trial

Diabetes Care(2020)10.2337/dc20-0279

N/A

1.9DataRank · unranked

61 citations

Robert D. Toto, Mark E. Cooper, Johannes F.E. Mann, Julio Rosenstock, Darren K. McGuire +12 more

Association between TNF Receptors and KIM-1 with Kidney Outcomes in Early-Stage Diabetic Kidney Disease

Clinical Journal of the American Society of Nephrology(2021)10.2215/cjn.08780621

N/A

1.4DataRank · unranked

48 citations

Taha Sen, Clare Arnott, Bruce Neal, Jos G. W. Kosterink, Kenneth W. Mahaffey +9 more

Chronic kidney disease

The Lancet(2021)10.1016/s0140-6736(21)00519-5

N/A

1.1DataRank · unranked

1430 citations

Tazeen H. Jafar, Dorothea Nitsch, Brendon L. Neuen, Vlado Perkovic, Kamyar Kalantar‐Zadeh

Effect of SGLT2 Inhibitors on Discontinuation of Renin–angiotensin System Blockade: A Joint Analysis of the CREDENCE and DAPA-CKD Trials

Journal of the American Society of Nephrology(2023)10.1681/asn.0000000000000248

N/A

0.995DataRank · unranked

39 citations

Niels Jongs, Glenn M. Chertow, John J.V. McMurray, Clare Arnott, Meg Jardine +11 more

Cardiovascular and Renal Outcomes with Canagliflozin According to Baseline Diuretic Use: A Post Hoc Analysis from the CANVAS Program

ESC Heart Failure(2021)10.1002/ehf2.13236

N/A

0.967DataRank · unranked

23 citations

Clare Arnott, Brendon L. Neuen, Hiddo L. Heersprink, Kenneth W. Mahaffey, Christopher P. Cannon +11 more

Sodium-Glucose Cotransporter-2 Inhibitors and Major Adverse Cardiovascular Outcomes: A SMART-C Collaborative Meta-Analysis

Circulation(2024)10.1161/circulationaha.124.069568

N/A

0.770DataRank · unranked

169 citations

Yu Mi Kang, KyungAh Im, Brendon L. Neuen, Stefan D. Anker, Deepak L. Bhatt +24 more

Analysis of on-treatment cancer safety events with daprodustat versus conventional erythropoiesis-stimulating agents—post hoc analyses of the ASCEND-ND and ASCEND-D trials

Nephrology Dialysis Transplantation(2022)10.1093/ndt/gfac342

N/A

0.767DataRank · unranked

11 citations

Finnian R. Mc Causland, Brian Claggett, Christoph Wanner, Andrzej Więcek, Michael B. Atkins +13 more

International consensus definitions of clinical trial outcomes for kidney failure: 2020

Kidney International(2020)10.1016/j.kint.2020.07.013

N/A

0.718DataRank · unranked

119 citations

Rajiv Agarwal, William G. Herrington, Hiddo J.L. Heerspink, Johannes F.E. Mann, Shahnaz Shahinfar +76 more

Blood pressure-lowering treatment for prevention of major cardiovascular diseases in people with and without type 2 diabetes: an individual participant-level data meta-analysis

The Lancet Diabetes & Endocrinology(2022)10.1016/s2213-8587(22)00172-3

N/A

0.701DataRank · unranked

106 citations

Zeinab Bidel, Dexter Canoy, Emma Copland, Derrick Bennett, Abbas Dehghan +95 more

Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial

Nephrology Dialysis Transplantation(2024)10.1093/ndt/gfae132

N/A

0.661DataRank · unranked

81 citations

Rajiv Agarwal, George L. Bakris, David Z.I. Cherney, Carolyn S.P. Lam, Brendon L. Neuen +95 more

Effect of Canagliflozin on Total Cardiovascular Burden in Patients With Diabetes and Chronic Kidney Disease: A Post Hoc Analysis From the CREDENCE Trial

Journal of the American Heart Association(2022)10.1161/jaha.121.025045

N/A

0.578DataRank · unranked

10 citations

Clare Arnott, Hiddo J.L. Heerspink, Qiang Li MBiostat, Christopher P. Cannon, David C. Wheeler +16 more

Association Between Circulating GDF‐15 and Cardio‐Renal Outcomes and Effect of Canagliflozin: Results From the CANVAS Trial

Journal of the American Heart Association(2021)10.1161/jaha.121.021661

N/A

0.524DataRank · unranked

32 citations

Jingwei Li, Brendon L. Neuen, Clare Arnott, Bruce Neal, Vlado Perkovic +6 more

Canagliflozin, Blood Pressure Variability, and Risk of Cardiovascular, Kidney, and Mortality Outcomes: Pooled Individual Participant Data From the CANVAS and CREDENCE Trials

Journal of the American Heart Association(2023)10.1161/jaha.122.028516

N/A

0.459DataRank · unranked

7 citations

Clare Arnott, Patrick Rockenschaub, Aletta E. Schutte, Lewis Carpenter, Muthiah Vaduganathan +13 more

Increase in BNP in Response to Endothelin-Receptor Antagonist Atrasentan Is Associated With Incident Heart Failure

JACC Heart Failure(2022)10.1016/j.jchf.2022.03.004

N/A

0.434DataRank · unranked

17 citations

Jeroen V. Koomen, Donald E. Kohan, John J.V. McMurray, George L. Bakris, Ricardo Correa‐Rotter +11 more

Primary and Secondary Cardiovascular and Kidney Prevention With Canagliflozin: Insights From the CANVAS Program and CREDENCE Trial

Journal of the American Heart Association(2024)10.1161/jaha.123.031586

N/A

0.405DataRank · unranked

7 citations

Amir Razaghizad, Abdulaziz Joury, Adeera Levin, Harpreet S. Bajaj, G.B. John Mancini +9 more

Evaluating Sibeprenlimab in IgA Nephropathy - Rationale and Baseline Data from the VISIONARY Trial

Kidney International Reports(2025)10.1016/j.ekir.2025.09.031

N/A

0.241DataRank · unranked

4 citations

Jonathan Barratt, Richard Lafayette, Adrian Liew, Yusuke Suzuki, Kevin Carroll +11 more

Sodium‐glucose co‐transporter‐2 inhibitors with and without metformin: A meta‐analysis of cardiovascular, kidney and mortality outcomes

Diabetes Obesity and Metabolism(2020)10.1111/dom.14226

N/A

0DataRank · unranked

78 citations

Clare Arnott, Vlado Perkovic, Gemma A. Figtree, Dick de Zeeuw, Greg Fulcher +8 more

SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation

Diabetes(2020)10.2337/dbi20-0040

N/A

0DataRank · unranked

124 citations

Frank C. Brosius, Matthew A. Cavender, Paola Fioretto, Kevin Fowler, Hiddo J.L. Heerspink +12 more

The effects of plasma exchange and glucocorticoids on early kidney function among patients with ANCA-associated vasculitis in the PEXIVAS trial

Kidney International(2024)10.1016/j.kint.2024.11.029

N/A

0DataRank · unranked

19 citations

Regina Riedl, Duvuru Geetha, Wladimir Szpirt, Carmel M. Hawley, Lisa Uchida +93 more

Impact of Canagliflozin on Kidney and Cardiovascular Outcomes by Type 2 Diabetes Duration: A Pooled Analysis of the CANVAS Program and CREDENCE Trials

Diabetes Care(2024)10.2337/dc23-1450

N/A

0DataRank · unranked

12 citations

David M. Charytan, Harpreet S. Bajaj, Adeera Levin, Navdeep Tangri, April Slee +6 more

Systemic Inflammation and the Risks of Adverse Kidney Outcomes in Adults With Atherosclerotic Cardiovascular Disease

American Journal of Kidney Diseases(2025)10.1053/j.ajkd.2025.04.011

N/A

0DataRank · unranked

10 citations

Edouard L. Fu, Anne-Laure Faucon, Paul Hjemdahl, Jimmi Mathisen, Iram Faqir Muhammad +5 more

Systematic Review of the Effects of Iron on Cardiovascular, Kidney, and Safety Outcomes in Patients With CKD

Kidney International Reports(2025)10.1016/j.ekir.2025.01.029

N/A

0DataRank · unranked

9 citations

Amanda Varghese, Sunil V. Badve, Roberto Pecoits‐Filho, Murilo Guedes, Clare Arnott +11 more

Interleukin-6 and Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: New Insights From CANVAS

Diabetes Care(2022)10.2337/dc22-0866

N/A

0DataRank · unranked

58 citations

Meir Schechter, Taha Sen, Priya Vart, Brendon L. Neuen, Bruce Neal +7 more

Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice

Kidney International(2020)10.1016/j.kint.2020.10.042

N/A

0DataRank · unranked

160 citations

Meg Jardine, Rajiv Agarwal, George L. Bakris, Christopher P. Cannon, David M. Charytan +15 more

Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria

Circulation(2023)10.1161/circulationaha.123.067584

N/A

0DataRank · unranked

312 citations

Hiddo J.L. Heerspink, Priya Vart, Brian Claggett, Robert A. Fletcher, Clare Arnott +11 more

Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes: the CARMELINA randomized controlled trial

Clinical Kidney Journal(2020)10.1093/ckj/sfaa225

N/A

0DataRank · unranked

18 citations

Mark E. Cooper, Odd Erik Johansen, Robert D. Toto, Julio Rosenstock, Darren K. McGuire +12 more

A meta-analysis of GFR slope as a surrogate endpoint for kidney failure

Nature Medicine(2023)10.1038/s41591-023-02418-0

N/A

0DataRank · unranked

160 citations

Willem Collier, Tom Greene, Shiyuan Miao, Juhi Chaudhari, Gerald B. Appel +79 more

Inter‐individual variability in atrasentan exposure partly explains variability in kidney protection and fluid retention responses: A post hoc analysis of the SONAR trial

Diabetes Obesity and Metabolism(2020)10.1111/dom.14252

N/A

0DataRank · unranked

21 citations

Jasper Stevens, George L. Bakris, Ricardo Correa‐Rotter, Fan Fan Hou, Dalane W. Kitzman +9 more

Vlado Perkovic

Indexed papers

Top data-sharing exemplar

Papers